|[August 29, 2013]
Nutra Pharma Announces Delivery of Nyloxin™ to New Vitality
CORAL SPRINGS, Fla. --(Business Wire)--
Nutra Pharma Corporation (OTCQB:NPHC), a biotechnology company that is
developing treatments for Multiple Sclerosis (MS), Human
Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain,
announced today that New Vitality (News - Alert), a marketing and distribution company,
has placed and received their first order of the Company's all-natural,
non-addictive pain reliever, Nyloxin®. The order was pursuant to New
Vitality's successful test radio campaign to gauge the market acceptance
of the product.
"This radio test represented the first broad exposure to our Nyloxin
brand," commented Rik J Deitsch, CEO of Nutra Pharma Corporation. "It's
been a pleasure working with New Vitality as they create awareness for
our products," he continued. "The radio advertising ran in major markets
across the US over several weeks, with a consumer response that was
positive enough to warrant the first orders from New Vitality. As things
progress, we expect to expand the relationship and have already worked
with New Vitality on our launch of Pet Pain-Away, our product for pain
in companion animals," concluded Mr. Deitsch.
Nyloxin™ is a homeopathic drug that utilizes proteins from cobra venom
to relieve pain and inflammation. An analgesic that began gaining U.S.
attention in 1936, cobra venom's effects in minute doses have been shown
by researchers to be superior to that of morphine, a highly addictive
opiate. The product is available in an easy-to-use oral spray for
treating: lower back pain, migraines, neck aches, shoulder pain, cramps
and neuralgia, as well as a topical gel for treating: repetitive stress,
arthritis and joint pain. Nyloxin™ is also available in Extra Strength
Additional benefits to Nyloxin™ include:
For the past 16 years New Vitality (www.newvitality.com)
has helped people live longer and look younger by marketing and selling
vitamins, health supplements, and personal care products. Customers
learn about their products from advertisements which use celebrities,
sport athletes and doctors to promote them on over 2000 radio and
television stations nationwide. New Vitality's catalog contains over 150
items which range from energy supplements to fruit and vegetable
supplements to colon cleanses and products for men's health.
A recent interview conducted by Christopher Castaldo, the CEO of Wall
Street Buy Sell Hold (www.wallstreetbuysellhold.com)
with Jonathan Flicker, the CEO of New Vitality can be viewed at: http://tinyurl.com/JF-interview
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company
specializing in the acquisition, licensing, and commercialization of
pharmaceutical products and technologies for the management of
neurological disorders, cancer, autoimmune, and infectious diseases,
including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV),
Adrenomyeloneuropathy (AMN) and Pain. The Company markets several drug
products for sale for the treatment of pain under the brands Cobroxin®
and Nyloxin™. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com
SEC (News - Alert) Disclaimer
This press release contains forward-looking statements. The words or
phrases "would be," "will allow," "intends to," "will likely result,"
"are expected to," "will continue," "is anticipated," "estimate,"
"project," or similar expressions are intended to identify
"forward-looking statements." Actual results could differ materially
from those projected in Nutra Pharma's ("the Company") business plan.
The delivery of Nyloxin to New Vitality should not be construed as an
indication in any way whatsoever of the future value of the Company's
common stock or its present or future financial condition. The Company's
filings may be accessed at the SEC's Edgar system at www.sec.gov.
Statements made herein are as of the date of this press release and
should not be relied upon as of any subsequent date. The Company
cautions readers not to place reliance on such statements. Unless
otherwise required by applicable law, we do not undertake, and we
specifically disclaim any obligation, to update any forward-looking
statements to reflect occurrences, developments, unanticipated events or
circumstances after the date of such statement.
Nutra Pharma Corp.
[ InfoTech Spotlight's Homepage ]